

DAFTAR PUSTAKA

1. Naeem S, Naz S, Riyaz A, Jehangir F, Afzal N. Original Article Immunohistochemical Analysis of Breast Cancer Subtypes and Their Correlation with Ki 67 Index. 2018;30(1):94–6.
2. Yersal, Ozlem; Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. *World J Clin Oncol*. 2014;5(3):412–25.
3. Li Z, Hu P, Tu J, Yu N. Luminal B breast cancer : patterns of recurrence and clinical outcome. 2016;7(40).
4. Bray F, Ferlay J, Soerjomataram I. Global Cancer Statistics 2018 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *Cancer J Clin*. 2018;68(6):394–424.
5. World Health Organization. Breast - Global Cancer Observatory. Vol. 256. 2019.
6. World Health Organization. WHO South-East Asia region (SEARO). Vol. 401. 2019.
7. Nasional KPK. Panduan Penatalaksanaan Kanker Payudara. Jakarta; 2015.
8. Zaha DC. Significance of immunohistochemistry in breast cancer. *World J Clin Oncol*. 2014;5(3):382–93.
9. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsy P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer : the St . Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol Off J Eur Soc Med Oncol*. 2017;28(8):1700–12.
10. Kondov B, Milenkovic Z, Kondov G, Petrushevska G, Basheska N. Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients. *Maced J Med Sci*. 2018;6(6):961–7.
11. Intan N, Wiguna P, Studi P, Dokter P, Kedokteran F, Udayana U. Karakteristik pemeriksaan imunohistokimia pada pasien kanker payudara di rsup sanglah periode 2003-2012. *E-Jurnal Med Udayana [Internet]*. 2014; Available from: <https://ojs.unud.ac.id/index.php/eum/article/view/9809>

12. Society E. What is Breast Cancer ? Let us answer some of your questions . [Internet]. European Society for Medical Oncology. Switzerland; 2018. Available from: <https://www.esmo.org/content/download/6593/114959/file/EN-Breast-Cancer-Guide-for-Patients.pdf>
13. American Cancer Society. Breast Cancer Facts & Figures 2017-2018. American Cancer Society. Atlanta; 2017.
14. World Health Organization. Indonesia - Global Cancer Observatory. Vol. 876. 2019.
15. Duraiyan J, Govindarajan R, Kaliyappan K. Applications of immunohistochemistry. *J Pharm Bioallied Sci.* 2012;4(August):307–10.
16. Matos LL De, Trufelli DC, Graciela M, Matos L De. Biomarker Insights Immunohistochemistry as an Important Tool in Biomarkers Detection and Clinical Practice. *Biomark Insight.* 2010;5:9–20.
17. Roh SKJ, Park C. Immunohistochemistry for Pathologists : Protocols , Pitfalls , and Tips. *J Pathol Transl Med.* 2016;50(6):411–8.
18. Blows FM, Driver KE, Schmidt MK, Broeks A, Leeuwen FE Van, Wesseling J, et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival : A Collaborative Analysis of Data for 10 , 159 Cases from 12 Studies. *PLoS Med.* 2010;7(5).
19. Williams C, Lin C. Oestrogen receptors in breast cancer : basic mechanisms and clinical implications. *Ecancermedicalsience.* 2013;7:370.
20. Badowska-kozakiewicz AM, Patera J, Sobol M. The role of oestrogen and progesterone receptors in breast cancer – immunohistochemical evaluation of oestrogen and progesterone receptor expression in invasive breast cancer in women. *Contemp Oncol.* 2015;19(3):220–5.
21. Ishikawa T, Ichikawa Y, Shimizu D, Sasaki T, Tanabe M, Chishima T, et al. The role of HER-2 in Breast Cancer. *J Surg Sci.* 2015;2(1):4–9.
22. Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers : Overexpression and Therapeutic Implications. *Mol Biol Int.* 2014;2014:852748.
23. Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. *Cancer Biol Med.* 2016;13(4):496–504.

24. Bustreo S, Paola SO, Michela C, Airoidi M, Pedani F, Papotti M, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation : a large case series study with a long-term follow-up. *Breast Cancer Res Treat.* 2016;157(2):363–71.
25. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Thürlimann B, Panel HS. Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol Off J Eur Soc Med Oncol.* 2013;24(9):2206–23.
26. Staging & Grade - Breast Pathology [Internet]. John Hopkins Pathology. [cited 2019 Nov 7]. Available from: <https://pathology.jhu.edu/breast/staging-grade/>
27. Makki J. Diversity of Breast Carcinoma : Histological Subtypes and Clinical Relevance. *Clin Med Insights Pathol.* 2015;8:23–31.
28. Sun Y, Zhao Z, Yang Z, Xu F, Lu H, Zhu Z, et al. Risk Factors and Preventions of Breast Cancer. *Int J Biol Sci.* 2017;13(11):1387–97.
29. Kamińska M, Ciszewski T, Łopacka-szatan K, Miotła P, Starosławska E. Breast cancer risk factors. *Prz menopauzalny = Menopause Rev.* 2015;14(3):196–202.
30. Leong SPL, Liu ZST, Derossis A, Cody H, Foulkes WD. Is Breast Cancer the Same Disease in Asian and Western Countries ? *World J Surg.* 2010;34(10):2308–24.
31. Yalaza M, İnan A, Bozer M. Male Breast Cancer. *J breast Heal.* 2016;12(1):1–8.
32. Khattab A, Monga DK. Cancer, Male Breast Cancer [Internet]. Treasure Island (FL): StatPearls Publishing; 2019. 2019 [cited 2019 Nov 13]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK526036/>
33. Lal P, Tan LK, Chen B. Correlation of HER-2 Status With Estrogen and Progesterone Receptors and Histologic Features in 3 , 655 Invasive Breast Carcinomas. *Am J Clin Pathol.* 2005;123(4):541–6.
34. Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, et al. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. *Breast Cancer Res.* 2017;19(1):83.
35. Siregar KB. Profil ekspresi HER2 dan Ki67 pada berbagai kelompok usia penderita kanker payudara di RSUP H . Adam Malik Medan. Vol. 46. 2013.

36. Setyawati Y, Rahmawati Y, Widodo I, Ghozali A, Purnomosari D. The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman. *Asian Pacific J cancer Prev APJCP*. 2018;19(5):1263–8.
37. Tesarova P. Breast cancer in the elderly — Should it be treated differently? *Reports Pract Oncol Radiother* [Internet]. 2013;18(1):26–33. Available from: <http://dx.doi.org/10.1016/j.rpor.2012.05.005>
38. Kumar, Vinay; Abbas, A; Aster J. *Robbins Pathologic Basis of Disease*. 9th ed. Philadelphia, PA: Elsevier/Saunders Ltd; 2013. 1055 p.